EICHOR
● Active Not Recruiting
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Condition: Melanoma · Sponsor: Bristol-Myers Squibb
About this study
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (149)
| Local Institution - 0125 | Phoenix, Arizona, United States | — |
| Local Institution - 0189 | Springdale, Arkansas, United States | — |
| Local Institution - 0098 | Los Angeles, California, United States | — |
| Local Institution - 0093 | Orange, California, United States | — |
| Local Institution - 0123 | Stanford, California, United States | — |
| Local Institution - 0113 | Englewood, Colorado, United States | — |
| Local Institution - 0114 | Jacksonville, Florida, United States | — |
| Local Institution - 0146 | Baltimore, Maryland, United States | — |
| Local Institution - 0071 | Rochester, Minnesota, United States | — |
| Local Institution - 0013 | Omaha, Nebraska, United States | — |
| Local Institution - 0169 | Cleveland, Ohio, United States | — |
| Local Institution - 0139 | Easton, Pennsylvania, United States | — |
+ 137 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05625399